Acute Myeloid Leukemia Clinical Trials in Columbus, Ohio

20 studies are recruiting for acute myeloid leukemia in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabi…

   Stage

   Phase 2

   Ages

   18 to 59

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   226 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05554406 on ClinicalTrials.gov

2. MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

   This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrom…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   349 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564390 on ClinicalTrials.gov

3. Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed in…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   227 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06317649 on ClinicalTrials.gov

4. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

   This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and …

   Stage

   Phase 3

   Ages

   0 to 21

   Site

   Nationwide Children's Hospital, Columbus, Ohio

   Locations

   206 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04293562 on ClinicalTrials.gov

5. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

   Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, …

   Stage

   Phase 1

   Ages

   0 and older

   Site

   Ohio State University, Columbus, Ohio

   Locations

   57 in total

   Run by

   Syndax Pharmaceuticals

   See if you can join NCT04065399 on ClinicalTrials.gov

6. A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

   The primary purpose of Phase 1 is to characterize the safety and tolerability to identify the recommended dose (RD) of Debio 1562M for further development. The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Ohio Sate University, Columbus, Ohio

   Locations

   7 in total

   Run by

   Debiopharm International SA

   See if you can join NCT06969430 on ClinicalTrials.gov

7. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

   This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

   Stage

   Not phased

   Ages

   40 to 75

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   745 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05334069 on ClinicalTrials.gov

8. Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

   The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and another protein called KMT2A in the leukemia cells. When this…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   US-Colombus OH-OSU, Columbus, Ohio

   Locations

   82 in total

   Run by

   Stichting Hemato-Oncologie voor Volwassenen Nederland

   See if you can join NCT07223814 on ClinicalTrials.gov

9. Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

   This phase II trial tests how well ziftomenib works in treating patients with NPM1 mutated or KMT2A rearranged acute myeloid leukemia (AML) and are not eligible to receive standard therapy. AML is often due to genetic changes in the cancer cells, including mutations in the NPM1 gene and rearrangeme…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Uma Borate

   See if you can join NCT06930352 on ClinicalTrials.gov

10. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

    Stage

    Phase 1

    Ages

    Up to 22

    Site

    Nationwide Children's Hospital, Columbus, Ohio

    Locations

    184 in total

    Run by

    PedAL BCU, LLC

    See if you can join NCT04726241 on ClinicalTrials.gov

11. A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

    This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene. SNDX-…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Locations

    23 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT05886049 on ClinicalTrials.gov

12. Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

    A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or…

    Stage

    Phase 3

    Ages

    0 to 21

    Site

    Nationwide Children's Hospital, Columbus, Ohio

    Locations

    90 in total

    Run by

    PedAL BCU, LLC

    See if you can join NCT05183035 on ClinicalTrials.gov

13. A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

    This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

    Stage

    Phase 1

    Ages

    12 to 78

    Site

    Ohio State University, Columbus, Ohio

    Locations

    12 in total

    Run by

    Orca Biosystems, Inc.

    See if you can join NCT03802695 on ClinicalTrials.gov

14. IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

    This phase II study compares the order of treatment with ivosidenib or enasidenib and azacitidine plus venetoclax in treating older patients with acute myeloid leukemia with genetic changes in the IDH1 or IDH2 genes (IDH mutated). Ivosidenib is in a class of medications called isocitrate dehydrogen…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Locations

    4 in total

    Run by

    Alice Mims

    See if you can join NCT05401097 on ClinicalTrials.gov

15. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

    This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

    Stage

    Phase 1

    Ages

    13 and older

    Site

    The Ohio State University, Columbus, Ohio

    Locations

    8 in total

    Run by

    Newave Pharmaceutical Inc

    See if you can join NCT04771572 on ClinicalTrials.gov

16. A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

    Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (o…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus, Ohio

    Locations

    71 in total

    Run by

    Taiho Oncology, Inc.

    See if you can join NCT04256317 on ClinicalTrials.gov

17. Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

    Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partial…

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    Ohio State University Medical Center, Columbus, Ohio

    Locations

    2 in total

    Run by

    University of Kansas Medical Center

    See if you can join NCT03533816 on ClinicalTrials.gov

18. Ziftomenib Maintenance Post Allo-HCT

    The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus, Ohio

    Locations

    2 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT06440135 on ClinicalTrials.gov

19. A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

    Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in pat…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The James Cancer Hospital and Solove Research Institute, Columbus, Ohio

    Locations

    44 in total

    Run by

    Kura Oncology, Inc.

    See if you can join NCT05735184 on ClinicalTrials.gov

20. Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML

    This is a phase I/II dose escalation study designed to determine the safety and estimate the efficacy of UD-NK cells combined with FLA chemotherapy in patients age 1-24.99 with relapsed or refractory acute myeloid leukemia. PRIMARY OBJECTIVE: I. To determine the safety and recommended phase II dose…

    Stage

    Phase 1

    Ages

    1 to 24

    Site

    Nationwide Children's Hospital, Columbus, Ohio

    Run by

    Nationwide Children's Hospital

    See if you can join NCT05503134 on ClinicalTrials.gov